YT 146

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341265

CAS#: 90596-75-1

Description: YT 146 is a biochemical.

Chemical Structure

YT 146
CAS# 90596-75-1

Theoretical Analysis

MedKoo Cat#: 341265
Name: YT 146
CAS#: 90596-75-1
Chemical Formula: C18H25N5O4
Exact Mass: 375.1907
Molecular Weight: 375.429
Elemental Analysis: C, 57.59; H, 6.71; N, 18.65; O, 17.05

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: YT 146; YT-146; YT146.

IUPAC/Chemical Name: Adenosine, 2-(1-octynyl)-


InChi Code: InChI=1S/C18H25N5O4/c1-2-3-4-5-6-7-8-12-21-16(19)13-17(22-12)23(10-20-13)18-15(26)14(25)11(9-24)27-18/h10-11,14-15,18,24-26H,2-6,9H2,1H3,(H2,19,21,22)/t11-,14-,15-,18-/m1/s1

SMILES Code: OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N=C(C#CCCCCCC)N=C32)N)O1)O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 375.429 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Sasamori J, Abe Y, Marunouchi T, Manome Y, Uchibori T, Tanonaka K. Effects of 2-Octynyladenosine (YT-146) on Mitochondrial Function in Ischemic/Reperfused Rat Hearts. Biol Pharm Bull. 2015;38(12):1946-53. doi: 10.1248/bpb.b15-00629. PubMed PMID: 26632185.

2: Sasamori J, Aihara K, Uchibori T, Takahashi A, Takeo S, Tanonaka K. Cardioprotective effects of 2-octynyladenosine (YT-146) in ischemic/reperfused rat hearts. J Cardiovasc Pharmacol. 2011 Feb;57(2):166-73. doi: 10.1097/FJC.0b013e318201c264. PubMed PMID: 21052018.

3: Sasamori J, Aihara K, Yoneyama F, Sato I, Kogi K, Takeo S. Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146). J Cardiovasc Pharmacol. 2006 Apr;47(4):614-20. PubMed PMID: 16680077.

4: Konno T, Murakami A, Uchibori T, Nagai A, Kogi K, Nakahata N. Involvement of adenosine A2a receptor in intraocular pressure decrease induced by 2-(1-octyn-1-yl)adenosine or 2-(6-cyano-1-hexyn-1-yl)adenosine. J Pharmacol Sci. 2005 Apr;97(4):501-9. Epub 2005 Apr 9. PubMed PMID: 15821340.

5: Harada N, Okajima K, Murakami K, Usune S, Sato C, Ohshima K, Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther. 2000 Sep;294(3):1034-42. PubMed PMID: 10945856.

6: Harada N, Okajima K, Katsuragi T. [Adenosine reduces ischemia/reperfusion-induced liver injury by inhibiting leukocyte activation]. Nihon Yakurigaku Zasshi. 1999 Oct;114 Suppl 1:159P-167P. Japanese. PubMed PMID: 10629874.

7: Yoneyama F, Aihara K, Kogi K, Satoh K, Taira N. Similarity and dissimilarity in mode and mechanism of action between YT-146, a selective adenosine receptor A2 agonist, and adenosine in isolated canine hearts. Tohoku J Exp Med. 1999 May;188(1):31-45. PubMed PMID: 10494898.

8: Ono T, Matsuoka I, Ohkubo S, Kimura J, Nakanishi H. Effects of YT-146 [2-(1-octynyl) adenosine], an adenosine A2A receptor agonist, on cAMP production and noradrenaline release in PC12 cells. Jpn J Pharmacol. 1998 Nov;78(3):269-77. PubMed PMID: 9869260.

9: Tanaka M, Takeda K, Takesako T, Takenaka K, Itoh H, Nakata T, Sasaki S, Nakagawa M. Altered cardiovascular responses to purinergic A2 stimulation in the nucleus tractus solitarius of spontaneously hypertensive rats. J Hypertens. 1995 Nov;13(11):1285-90. PubMed PMID: 8984126.

10: Takiguchi Y, Nagano M, Ikeda Y, Nakashima M. Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury. Eur J Pharmacol. 1995 Aug 4;281(2):205-7. PubMed PMID: 7589208.

11: Abiru T, Endo K, Machida H. Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A2 receptor agonist, in the isolated rat femoral artery and vein. Eur J Pharmacol. 1995 Jul 25;281(1):9-15. PubMed PMID: 8566123.

12: Iwamoto T, Umemura S, Toya Y, Hirawa N, Takeda K, Kihara M, Ishii M. Antihypertensive effects of 2-octynyladenosine (YT-146), a selective adenosine A2 receptor agonist, in Dahl salt-sensitive rats. Am J Hypertens. 1994 Nov;7(11):984-8. PubMed PMID: 7848625.

13: Makujina SR, Olanrewaju HA, Mustafa SJ. Evidence against KATP channel involvement in adenosine receptor-mediated dilation of epicardial vessels. Am J Physiol. 1994 Aug;267(2 Pt 2):H716-24. PubMed PMID: 8067427.

14: Iwamoto T, Umemura S, Toya Y, Uchibori T, Kogi K, Takagi N, Ishii M. Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10. PubMed PMID: 8135838.

15: Furukawa S, Satoh K, Taira N. Opening of ATP-sensitive K+ channels responsible for adenosine A2 receptor-mediated vasodepression does not involve a pertussis toxin-sensitive G protein. Eur J Pharmacol. 1993 May 19;236(2):255-62. PubMed PMID: 8319753.

16: Yoneyama F, Yamada H, Satoh K, Taira N. Vasodepressor mechanisms of 2-(1-octynyl)-adenosine (YT-146), a selective adenosine A2 receptor agonist, involve the opening of glibenclamide-sensitive K+ channels. Eur J Pharmacol. 1992 Mar 24;213(2):199-204. PubMed PMID: 1521559.

17: Kogi K, Uchibori T, Aihara K, Yamaguchi T, Abiru T. Pharmacological profile of the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146) in the cardiovascular system. Jpn J Pharmacol. 1991 Oct;57(2):153-65. PubMed PMID: 1812297.

18: Abiru T, Yamaguchi T, Watanabe Y, Kogi K, Aihara K, Matsuda A. The antihypertensive effect of 2-alkynyladenosines and their selective affinity for adenosine A2 receptors. Eur J Pharmacol. 1991 Apr 10;196(1):69-76. PubMed PMID: 1874281.